Through the identification of new dosage-sensitive genes in children with DS and leukaemia, several groups have shown that targeting the product of the chromosome 21 genes HMGN1 and DYRK1A may be broadly applicable to many blood cancers and potentially solid tumours [158,159,165]. Here, DYRK1A is linked to Dravet syndrome.